Celecoxib — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Pain

• Gabapentin
• Pregabalin
• Diclofenac
• Duloxetine
• Ibuprofen
• Ketorolac
• Meloxicam
• Naproxen

Other medications in Musculoskeletal

• Colchicine
• Febuxostat
• Ibandronate
• Indomethacin
• Raloxifene
• Risedronate
• Acetaminophen
• Alendronate

What Celecoxib is approved for (FDA label)

Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [see Clinical Studies (14.1)] . 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA [see Clinical Studies (14.2)] . 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3)] . 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS [see Clinical Studies (14.4)] . 1.5 Acute Pain For the management of acute pain in adults [see Clinical Studies (14.5)] . 1.6 Primary Dysmenorrhea For the management of primary dysmenorrhea [see Clinical Studies (14.5)] .

Source: Read the full FDA label on DailyMed. Label effective date: September 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Celecoxib (FDA label)

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1)] . • Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)] . Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)] . WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Celecoxib (FDA label)

Celecoxib capsules: • 50 mg are opaque white/opaque white hard gelatin capsules size “5” having imprinting “134” on body with red ink and “A” on cap with red ink filled with white to off-white colored granular powder. • 100 mg are opaque white/opaque white hard gelatin capsules size “3” having imprinting “135” on body with blue ink and “A” on cap with blue ink filled with white to off-white colored granular powder. • 200 mg are opaque white/opaque white hard gelatin capsules size “1” having imprinting “136” on body with golden yellow ink and “A” on cap with golden yellow ink filled with white to off-white colored granular powder.

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Celecoxib (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: · Cardiovascular Thrombotic Events [see Warnings and Precautions (5.1)] · GI Bleeding, Ulceration and Perforation [see Warnings and Precautions (5.2)] · Hepatotoxicity [see Warnings and Precautions (5.3)] · Hypertension [see Warnings and Precautions (5.4)] · Heart Failure and Edema [see Warnings and Precautions (5.5)] · Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6)] · Anaphylactic Reactions [see Warnings and Precautions (5.7)] · Serious Skin Reactions [see Warnings and Precautions (5.9)] · Hematologic Toxicity [see Warnings and Precautions (5.12)] Most common adverse reactions in arthritis trials (>2% and >placebo) are: abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Celecoxib (FDA label)

Celecoxib is contraindicated in the following patients: • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see Warnings and Precautions (5.7, 5.9)] . • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [see Warnings and Precautions (5.7, 5.8)] . • In the setting of CABG surgery [see Warnings and Precautions (5.1)] . • In patients who have demonstrated allergic-type reactions to sulfonamides [see Warnings and Precautions (5.7)] . • Known hypersensitivity to celecoxib, or any components of the drug product or sulfonamides. ( 4 ) • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. ( 4 ) • In the setting of CABG surgery. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Celecoxib (FDA label)

• Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. ( 5.3 ) • Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. ( 5.4 , 7 ) • Heart Failure and Edema: Avoid use of celecoxib in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. ( 5.5 ) • Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Celecoxib (FDA label)

See Table 3 for clinically significant drug interactions with celecoxib. Table 3: Clinically Significant Drug Interactions with Celecoxib Drugs that Interfere with Hemostasis Clinical Impact: • Celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. • Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.

Source: FDA prescribing information (DailyMed). Set ID: 3a1eadd5-c0a7-473e-bde0-6b9450d11c95. SPL document ID: 4c165daf-efed-4c93-9add-e81a4523946d. Label effective date: September 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.